Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.46 |
| ▸ | GAA | P10253 | 2/20 | 0.46 |
| ▸ | KMT2A | Q03164 | 5/20 | 0.46 |
| ▸ | MAPT | P10636 | 4/20 | 0.46 |
| ▸ | MEN1 | O00255 | 3/20 | 0.46 |
| ▸ | CNR1 | P21554 | 1/20 | 0.44 |
| ▸ | NTRK1 | P04629 | 3/20 | 0.43 |
| ▸ | NTRK2 | Q16620 | 3/20 | 0.43 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.43 |
| ▸ | POLB | P06746 | 2/20 | 0.42 |
| ▸ | TP53 | P04637 | 1/20 | 0.42 |
| ▸ | TSHR | P16473 | 1/20 | 0.42 |
| ▸ | CASP1 | P29466 | 1/20 | 0.42 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.42 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.42 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.42 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.42 |
| ▸ | MCL1 | Q07820 | 1/20 | 0.42 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.42 |
| ▸ | NPC1 | O15118 | 2/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3389373 | 0.92 | ALDH1A1 (0.49) | ALDH1A1GAAKMT2AMAPTMEN1 | |
| SCHEMBL3389377 | 0.85 | KMT2A (0.41) | ALDH1A1GAAKMT2AMAPTMEN1 | |
| SCHEMBL3393090 | 0.83 | NPC1 (0.48) | GAAKMT2AMAPTMEN1TDP1 | |
| SCHEMBL3390148 | 0.81 | CHRNA7 (0.48) | KMT2AMAPTMEN1POLBTP53 | |
| SCHEMBL3388415 | 0.81 | PDE5A (0.43) | KMT2AMEN1TP53NPSR1SMN1; SMN2 | |
| SCHEMBL3325793 | 0.80 | SCN5A (0.58) | ALDH1A1MAPTSMN1; SMN2NPC1RAB9A | |
| SCHEMBL3390544 | 0.79 | ABCB1 (0.44) | MAPTTP53NPSR1KDM4ENPC1 | |
| SCHEMBL3388395 | 0.79 | NPC1 (0.46) | KMT2AMAPTMEN1POLBKDM4E | |
| SCHEMBL3331566 | 0.79 | MMP13 (0.48) | ALDH1A1KMT2AMAPTMEN1POLB | |
| SCHEMBL3391378 | 0.79 | CHRNA7 (0.41) | POLBTP53SMN1; SMN2NPC1RAB9A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1713810-B1 | DIAZABICYCLIC ARYL DERIVATIVES AS NICOTINIC ACETYLCHOLINE RECEPTOR LIGANDS | NEUROSEARCH AS (DK) | 2010-12-29 | — | — | EP | claimed |
| US-20100130482-A1 | DIAZABICYCLIC ARYL DERIVATIVES AS NICOTINIC ACETYLCHOLINE RECEPTOR LIGANDS | PETERS DAN | 2010-05-27 | — | — | US | claimed |
| US-20080227772-A1 | Diazabicyclic Aryl Derivatives as Nicotinic Acetylcholine Receptor Ligands | NEUROSEARCH A/S | 2008-09-18 | — | — | US | claimed |
| EP-1713810-A1 | DIAZABICYCLIC ARYL DERIVATIVES AS NICOTINIC ACETYLCHOLINE RECEPTOR LIGANDS | NEUROSEARCH A/S (DK) | 2006-10-25 | — | — | EP | claimed |
| WO-2005075482-A1 | DIAZABICYCLIC ARYL DERIVATIVES AS NICOTINIC ACETYLCHOLINE RECEPTOR LIGANDS | NEUROSEARCH A/S (DK) | 2005-08-18 | — | — | WO | claimed |
| EP-1713810-B1 | DIAZABICYCLIC ARYL DERIVATIVES AS NICOTINIC ACETYLCHOLINE RECEPTOR LIGANDS | NEUROSEARCH AS (DK) | 2010-12-29 | — | — | EP | disclosed |
| US-20100130482-A1 | DIAZABICYCLIC ARYL DERIVATIVES AS NICOTINIC ACETYLCHOLINE RECEPTOR LIGANDS | PETERS DAN | 2010-05-27 | — | — | US | disclosed |
| US-20080227772-A1 | Diazabicyclic Aryl Derivatives as Nicotinic Acetylcholine Receptor Ligands | NEUROSEARCH A/S | 2008-09-18 | — | — | US | disclosed |
| EP-1713810-A1 | DIAZABICYCLIC ARYL DERIVATIVES AS NICOTINIC ACETYLCHOLINE RECEPTOR LIGANDS | NEUROSEARCH A/S (DK) | 2006-10-25 | — | — | EP | disclosed |
| WO-2005075482-A1 | DIAZABICYCLIC ARYL DERIVATIVES AS NICOTINIC ACETYLCHOLINE RECEPTOR LIGANDS | NEUROSEARCH A/S (DK) | 2005-08-18 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100130482-A1 | DIAZABICYCLIC ARYL DERIVATIVES AS NICOTINIC ACETYLCHOLINE RECEPTOR LIGANDS | CHRNA6, CHRNA10, CHRNA2 | ALDH1A1 1094/4885GAA 3254/4885KMT2A 1673/4885 |
| US-20080227772-A1 | Diazabicyclic Aryl Derivatives as Nicotinic Acetylcholine Receptor Ligands | CHRNA6, CHRNA10, CHRNA2 | ALDH1A1 1094/4885GAA 3254/4885KMT2A 1673/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.